MiR-301b-3p promotes breast cancer development through inhibiting the expression of transforming growth factor-beta receptor 2

被引:0
作者
Lou, Jian [1 ]
Liu, Xueni [1 ]
Xie, Yanru [1 ]
Wu, Minhua [1 ]
Mao, Weibo [2 ]
Ying, Xiaozhen [1 ]
机构
[1] Lishui Cent Hosp, Tumor Ctr, Lishui, Peoples R China
[2] Lishui Cent Hosp, Pathol Dept, Lishui, Peoples R China
来源
PEERJ | 2024年 / 12卷
关键词
MiR-301b-3p-inhibitor; Transforming growth factor-beta receptor 2 (TGFBR2); Transwell assay; Breast cancer; Antagonism of miR-301b-3p and TGFBR2; MICRORNAS; TGFBR2; TARGET; STAT3;
D O I
10.7717/peerj.18324
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background. Breast cancer (BC) is a serious health threat to the patients. The present work explored the mechanism of miR-301b-3p and transforming growth factor-beta receptor 2 (TGFBR2 ) in affecting BC progression. Methods. The miR-301b-3p-inhibitor and si-TGFBR2 solution were added to the DEME/F12 medium to culture the BC and normal breast epithelial cell lines to prepare negative control, miR-301b-3p-IN and miR-301b-3p-IN+si-TGFBR2 in the two types of cell lines. The relative expression of target genes and the interference effect were analyzed by quantitative real-time PCR (qRT- PCR). Cell viability was detected applying cell counting kit-8 (CCK-8) assay. Transwell and wound healing assay were conducted to evaluate the invasion and migration of BC cells after miR-301b-3p inhibition. Additionally, cell apoptosis and the expression STAT protein were measured by flow cytometry and Western blot, respectively Results. The qRT-PCR results showed that miR-301b-3p were high-expressed but the level of TGFBR2 was significantly inhibited in BC cells. The miR-301b-3p-inhibitor significantly downregulated the expression of miR-301b-3p and upregulated that of TGFBR2. Meanwhile, inhibition of miR-301b-3p suppressed the cell viability, invasion, and migration of BC cells, which, however, were restored by the inhibition of TGFBR2. MiR-301b-3p conferred anti-apoptosis ability to BC cells, while TGFBR2 promoted apoptosis of BC cells through producing an antagonistic effect with miR-301b-3p. We found that miR-301b-3p played a crucial role in the phosphorylation of STAT1 and STAT3 to promote BC progression. Conclusion. The present findings demonstrated that miR-301b-3p played a crucial role in promoting BC cell growth, invasion and migration and anti-apoptosis, and that targeting TGFBR2 could inhibit the tumor-promoting effect of miR-301b-3p.
引用
收藏
页数:19
相关论文
共 65 条
  • [21] Li CJ, 2017, METHODS MOL BIOL, V1524, P149, DOI 10.1007/978-1-4939-6603-5_9
  • [22] STAT proteins in cancer: orchestration of metabolism
    Li, Yi-Jia
    Zhang, Chunyan
    Martincuks, Antons
    Herrmann, Andreas
    Yu, Hua
    [J]. NATURE REVIEWS CANCER, 2023, 23 (03) : 115 - 134
  • [23] Liu H., 2021, TECHNOL CANCER RES T, V20, DOI DOI 10.1177/1533033821990036
  • [24] Cuproptosis and cuproptosis-related genes: Emerging potential therapeutic targets in breast cancer
    Liu, Xiangdong
    Luo, Bo
    Wu, Xinhong
    Tang, Zijian
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (06):
  • [25] YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer
    Lo Sardo, Federica
    Pulito, Claudio
    Sacconi, Andrea
    Korita, Etleva
    Sudol, Marius
    Strano, Sabrina
    Blandino, Giovanni
    [J]. CANCER LETTERS, 2021, 500 : 51 - 63
  • [26] Lu XQ, 2021, CRIT REV EUKAR GENE, V31, P35, DOI 10.1615/CritRevEukaryotGeneExpr.2021038215
  • [27] Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/β-catenin signaling
    Ma, Fei
    Zhang, Jianguo
    Zhong, Lei
    Wang, Lei
    Liu, Yansong
    Wang, Yimin
    Peng, Lin
    Guo, Baoliang
    [J]. GENE, 2014, 535 (02) : 191 - 197
  • [28] USP13 functions as a tumor suppressor by blocking the NF-kB-mediated PTEN downregulation in human bladder cancer
    Man, Xiaojun
    Piao, Chiyuan
    Lin, Xuyong
    Kong, Chuize
    Cui, Xiaolu
    Jiang, Yuanjun
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
  • [29] Maren Nathan A, 2023, Methods Mol Biol, V2653, P317, DOI 10.1007/978-1-0716-3131-7_20
  • [30] Martinotti S, 2020, METHODS MOL BIOL, V2109, P225, DOI 10.1007/7651_2019_259